Evidence map›Paper›PMID 35051021›Full record

ArticleToxins2022

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.

Harald Hefter, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, Sven G Meuth, John-Ih Lee, Philipp Albrecht, Sara Samadzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Harald HefterDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.ORCID 0000-0003-1069-7684
Beyza ÜrerDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Raphaela BraunsDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Dietmar RosenthalDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Sven G MeuthDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
John-Ih LeeDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Philipp AlbrechtDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Sara SamadzadehDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under continuous long-term treatment with abo- or onabotulinum toxin type A (BoNT/A), ~10 to 15% of patients with cervical dystonia (CD) will develop neutralizing antibodies and reduced responsiveness over an ~10-year treatment period. Among the botulinum neurotoxin type A preparations so far licensed for CD, incobotulinum toxin A (incoBoNT/A; Xeomin

Indexed as

AdultBotulinum Toxins, Type ACross-Sectional StudiesFemaleHumansMaleMiddle AgedMuscle SpasticityNeuromuscular AgentsRetrospective StudiesTorticollisToxins, BiologicalTreatment FailureBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular AgentsToxins, Biologicalcomplex proteinsincobotulinum toxinlow antigenicityneutralizing antibodiessecondary treatment failure

Identifiers

PMID35051021
PMCPMC8779547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.